Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Consummate the Specialty of Handshaking in Business and Group environments - 2Viable Monetary Tips to Advance Your Monetary Circumstance
- 3Cannabis reclassification could 'open the floodgates' for research, scientists say
- 4Artemis 2 astronauts are about to see one of the rarest skywatching sights of all — a solar eclipse from beyond the moon
- 5Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- The Most Compelling Books of the 10 years
- The Best 15 Applications for Efficiency and Association
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- Wedding trip Objections in Europe
- Journalists killed by Israeli strike in southern Lebanon
- Reactions as Artemis II astronauts lift off on historic lunar mission
- The 15 Most Rousing TED Chats on Self-awareness
- Investigate Business Mastercard Choices for Better Rewards and Rewards
- When preventable infections turn deadly behind bars | The Excerpt
